United Kingdom Flu Diagnostic And Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

The United Kingdom flu diagnostic and treatment market is projected to grow at a CAGR of 14.98% throughout the forecast period to reach US$4,487.979 million in 2027, from US$1,689.332 million in 2020.

The growth of flu diagnostics and treatment in the United Kingdom is majorly attributed to the presence of the state-of-the-art healthcare infrastructure of the country coupled with a moderate incidence of seasonal flu throughout the country. The market’s growth is positively impacted by the continuously spreading incidence of flu throughout the country. However, the impact is projected to decrease over the coming years, which is one factor projected to moderately impact the market growth of flu diagnostics and treatments in the upcoming years. This is further leading to a significant reduction in the number of medical visits that are related to flu-like illnesses. Furthermore, the number of hospitalizations and intensive care admissions are also projected to decrease over the coming years, thereby hindering the market growth of flu diagnostics and treatments in the short run.

The United Kingdom flu diagnostic and treatment market is expected to grow due to the seasonal flu outbreaks, increased healthcare expenditure, and others.

However, the outbreak of seasonal flu in the country is considered one of the factors which are expected to significantly drive the market growth in the country. Similarly, a significant increase in healthcare expenditure is also projected to support the flu diagnostic and treatment market growth throughout the forecast period. According to the Office of National Statistics of the UK, the current healthcare expenditure in 2020 was GBP 257.6 billion (314.25 billion USD). UK’s healthcare expenditure in 2020 accounted for 12% of its GDP, compared with 9.9% in 2019. Furthermore, the availability of a well-established free public-funded healthcare system is also leading to the adoption of costly treatments and services, thereby driving the demand for flu diagnostics and tests and adding to the market’s growth significantly. The National Health Service (NHS) is the program that is available to the permanent residents of the UK, which also offers free healthcare to them.SE

Product Offerings

• The A. Menarini Diagnostics of the UK offers Influenza and COVID-19 AG combo rapid test, that facilitates patients with easy diagnostics. It is a simple and time-saving procedure, as all the required tools are provided with the kit and there is no need for external equipment.
• F. Hoffmann-La Roche Ltd. provides the Cobas® SARS-CoV- 2 and Influenza A & B tests. The company claims that the test kit can differentiate between COVID-19 and Flu. The test only takes 20 mins with minimum cross-contamination and risk of exposure during testing with the closed-system design.
• Abbott’s introduced ID NOWTM Influenza A & B 2 assay that provides molecular flu results in 13 minutes or less, which is significantly faster than other molecular methods and more accurate than traditional rapid tests. The ability to make efficient treatment decisions is made possible by rapid diagnostic procedures with increased sensitivity.

COVID-19 Insights

The UK health security agency published a report in July 2022 on Weekly national Influenza and COVID-19 surveillance. A total of 1079 participants completed the weekly surveillance out of which 90 (8.3%) reported fever or cough and 23 (2.1%) reported influenza-like illness. The report highlights that at a national level when COVID-19 activity increased, influenza activity remained very low through most indicators. Since the healthcare sector was overburdened with COVID-19 patients, the diagnostics and therapeutics for influenza cases declined to affect the market potential in 2020.

Segmentation

• By Type of Flu
  • Type A
  • Type B
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • Others
  • Therapeutics
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By End-User
  • Hospital Laboratory
  • Outpatient Clinic
  • Reference Laboratory